CYTOFLAVIN

In adults in complex therapy:

consequences of a brain infarction,

other cerebrovascular diseases (cerebral atherosclerosis, hypertensive encephalopathy),

neurasthenia (increased irritability, fatigue, loss of ability to long-term mental and physical stress).

Inside, according to 2 tables. 2 times a day with an interval between doses of 8-10 hours. Tablets should be taken at least 30 minutes before meals, without chewing, with water (100 ml).

It is recommended to take the drug in the morning and during the day (no later than 18 hours).

The duration of the course of treatment is 25 days. The appointment of a repeat course is possible with an interval of at least 1 month.

Individual intolerance to the components of the drug.

It is not recommended for use in children under 18 years of age due to insufficient data on efficacy and safety.

With caution: diseases of the digestive system (erosion, ulcers of the stomach and / or duodenum, gastritis and duodenitis (in the acute stage), hypotension, nephrolithiasis, concomitant gout, hyperuricemia. If the patient has one of these diseases, you should consult your doctor before taking the drug.

Headache, pain or discomfort in the epigastric region. Allergic reactions in the form of skin hyperemia and itching are possible. Adverse reactions include: transient hypoglycemia, hyperuricemia, exacerbation of concomitant gout.

If any of the side effects listed in the instructions are aggravated or the patient has noticed any other side effects not listed in the instructions, you should inform your doctor.

To date, cases of overdose of the drug Cytoflavin^® they were not installed.

Pharmacological effects are due to the complex effect of the Cytoflavin components of the drug^® components.

Succinic acid — an endogenous intracellular metabolite of the Krebs cycle, which performs a universal energy-synthesizing function in the cells of the body.

With the participation of the coenzyme flavinadenine dinucleotide (FAD), succinic acid is rapidly transformed by the mitochondrial enzyme succinate dehydrogenase into fumaric acid and then into other metabolites of the tricarboxylic acid cycle. It stimulates aerobic glycolysis and ATP synthesis in cells.

The end product of succinic acid metabolism in the Krebs cycle is carbon dioxide and water. Succinic acid improves tissue respiration through activation of electron transport in the mitochondria.

Riboflavin (vitamin B₂) is a FAD coenzyme that activates succinate dehydrogenase and other redox reactions of the Krebs cycle.

Nicotinamide (vitamin PP)  the amide of nicotinic acid. Nicotinamide in cells, through a cascade of biochemical reactions, is transformed into the form of nicotinamide adenine nucleotide (NAD) and its phosphate (NADP), activating nicotinamide-dependent Krebs cycle enzymes necessary for cellular respiration and stimulation of ATP synthesis.

Inosine it is a purine derivative, a precursor of ATP. It has the ability to activate a number of enzymes of the Krebs cycle, stimulating the synthesis of key enzymes-nucleotides: FAD and NAD.

Thus, all components of the drug Cytoflavin^® they are natural metabolites of the body and stimulate tissue respiration. The metabolic energy correction, antihypoxic and antioxidant activity of the drug, which determine its pharmacological properties and therapeutic effectiveness, are due to the complementary action of succinic acid, inosine, nicotinamide and riboflavin.

Cytoflavin^® it has a high bioavailability.

Succinic acid when ingested, it penetrates from the gastrointestinal tract into the blood and tissues, participating in the reactions of energy metabolism, and completely disintegrates to the final products of metabolism (carbon dioxide and water) after 30 minutes.

Inosine it is well absorbed from the gastrointestinal tract. T_max in the blood — 5 h, the average retention time in the blood — 5.5 h, V_ss - about 20 l. Inosine is metabolized in the liver to form inosine monophosphate, followed by its oxidation to uric acid. In a small amount, it is excreted by the kidneys.

Nicotinamide quickly distributed in all tissues (V_ss about 500 l). T_max in the blood-2 hours, the average retention time in the blood-4.5 hours. Nicotinamide penetrates through the placenta and into breast milk, is metabolized in the liver to form N-methylnicotinamide, is excreted by the kidneys.

Riboflavin it is rapidly absorbed from the gastrointestinal tract, distributed unevenly (the largest amount in the myocardium, liver, kidneys), transformed into flavinadenin mononucleotide (FMN) and FAD in the mitochondria. It penetrates through the placenta and into breast milk, is excreted by the kidneys, mainly in the form of metabolites.

• Metabolic agent [Other metabolics in combination]

Succinic acid, inosine, and nicotinamide are compatible with other medications. Riboflavin reduces the activity of certain antibiotics (tetracyclines, erythromycin, lincomycin), is incompatible with streptomycin. Ethanol, tricyclic antidepressants, and tubular secretion blockers reduce the absorption of riboflavin, and thyroid hormones accelerate its metabolism.

In a place protected from light, at a temperature not exceeding 25 °C.

Keep out of reach of children.

Do not use after the expiration date indicated on the package.

Tablets coated with an intestinal-soluble coating. In a contour cell package made of PVC film and aluminum foil for packaging or from a combined material based on aluminum foil and aluminum foil for packaging, 10 pcs. 5 or 10 contour cell packages in a pack of cardboard.

It is not recommended to take it during pregnancy and lactation due to the lack of clinical data on the effectiveness and safety of the drug during this period.

According to the recipe.

With hypertension, it may be necessary to adjust the doses of antihypertensive drugs.

In patients with diabetes mellitus, treatment should be carried out under the control of the concentration of glucose in the blood.

Possible intensive staining of urine in yellow color.

Influence on the ability to drive vehicles and work with mechanisms. Cytoflavin^® it does not affect the ability to drive vehicles, work with moving mechanisms, the work of dispatchers and operators.

N07XX Other drugs for the treatment of diseases of the nervous system

• E63 Physical and mental overload
• F48. 0 Neurasthenia
• I67. 2 Cerebral atherosclerosis
• I67. 4 Hypertensive encephalopathy
• I67. 9 Cerebrovascular disease, unspecified
• I69. 3 Consequences of a brain infarction
• I69. 4 Consequences of stroke, not specified as hemorrhage or cerebral infarction
• R45. 4 Irritability and anger
• R53 Malaise and fatigue

Pills: round biconvex, covered with a red shell. Two layers are visible on the cross-section. The core is yellow to yellow-orange in color.